Ambulero, Inc. is at the forefront of developing innovative cell and gene therapies aimed at treating vascular diseases. Central to their approach is the use of E-selectin, a cell adhesion molecule that plays a crucial role in tissue repair. The company has two primary treatment modalities: one involves the use of engineered mesenchymal stromal cells (MSCs), referred to as "Supercharged MSCs," which are designed to enhance tissue healing by expressing E-selectin. The second modality utilizes adeno-associated virus (AAV) vectors to deliver E-selectin directly to damaged tissues, thereby promoting regeneration and healing in conditions such as critical limb ischemia and other vascular diseases.

Ambulero's flagship gene therapy product, AMB-301, is specifically targeted at a rare form of vascular disease that currently lacks effective treatment options, with amputation being a last resort for some patients. The company is also developing AMB-201 for critical limb ischemia, a condition affecting millions of individuals, particularly those with diabetes. Through these advanced therapies, Ambulero aims to provide new hope for patients suffering from vascular diseases, while also pursuing research collaborations to enhance the development and accessibility of their innovative treatments.

United States

Ambulero is a cell and gene therapy spin-out of the University of Miami focused on advancing new therapies to fight vascular disease. We are a platform company that can deliver the adhesion molecule E-selectin using different cell and synthetic vector technologies. We work on rare vascular diseases as well as more common indications effecting large patient populations.

Ambulero

Company Details